Perioperative Venous Thromboembolism Chemoprophylaxis Does Not Increase Risk of Complications in Free Flap Breast Reconstruction
Journal of Surgical Oncology · 2025
DOI: 10.1002/jso.28030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2025. Verfasst von Francis D Graziano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Mammaplasty, Free Tissue Flaps, Postoperative Complications. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, This research was supported by NIH/NCI Cancer Center Support (Grant P30 CA008748)..
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Patients undergoing abdominal‐based free flap breast reconstruction are at risk for perioperative venous thromboembolism (VTE), but the optimal anticoagulation protocol remains unknown. We hypothesized that a standardized chemoprophylaxis protocol would minimize VTE events without increasing hematoma, flap loss, or reoperation.
Methods
A retrospective review was conducted on patients who underwent abdominal‐based free flap breast reconstruction from 2010 to 2023. In 2015, we implemented an enhanced recovery after surgery (ERAS) protocol including preoperative enoxaparin. Patients with a BMI < 30 and > 30 received enoxaparin for 7 and 30 days postoperatively, respectively. 2010–2015 patients were pre‐ERAS and 2015–2023 patients were the ERAS cohort. Patient demographics, comorbidities, and outcomes were analyzed. The primary outcomes were VTE, hematoma, flap loss, and reoperation.
Results
2317 patients were included: 679 were pre‐ERAS and 1638 were in the ERAS cohort. The incidence of deep vein thrombosis (0.7%) and pulmonary embolism (pre‐ERAS 0.6% vs. ERAS 0.5%) was low in both cohorts with no significant differences. Hematoma (pre‐ERAS 7.2% vs. ERAS 5.5%) and reoperation (pre‐ERAS 7.8% vs. ERAS 9.7%) were similar, but the ERAS cohort had significantly lower flap failure (0.7% vs. 2.1%, p < 0.05).
Conclusions
A standardized perioperative anticoagulation protocol for abdominal‐based breast reconstruction maintained low VTE rates without increasing hematoma, flap failure, or reoperation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Plastic and Reconstructive Surgery Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
ORCID-Profile: Robert J Allen, Jonas A Nelson
Förderung
- NCI NIH HHS
- This research was supported by NIH/NCI Cancer Center Support (Grant P30 CA008748).
Zitieren
APA
Graziano, F. D., Amakiri, U. O., Levy, J., Shammas, R. L., Rubin, J., Boe, L., Matros, E., Mehrara, B. J., Allen, R. J., & Nelson, J. A. (2025). Perioperative Venous Thromboembolism Chemoprophylaxis Does Not Increase Risk of Complications in Free Flap Breast Reconstruction. Journal of Surgical Oncology. https://doi.org/10.1002/jso.28030
Vancouver
Graziano FD, Amakiri UO, Levy J, Shammas RL, Rubin J, Boe L, et al. Perioperative Venous Thromboembolism Chemoprophylaxis Does Not Increase Risk of Complications in Free Flap Breast Reconstruction. Journal of Surgical Oncology. 2025. doi:10.1002/jso.28030
BibTeX
@article{Graziano2025,
author = {Graziano, Francis D and Amakiri, Uchechukwu O and Levy, Jacob and Shammas, Ronnie L and Rubin, Jonathan and Boe, Lillian and Matros, Evan and Mehrara, Babak J and Allen, Robert J and Nelson, Jonas A},
title = {Perioperative Venous Thromboembolism Chemoprophylaxis Does Not Increase Risk of Complications in Free Flap Breast Reconstruction},
journal = {Journal of Surgical Oncology},
year = {2025},
doi = {10.1002/jso.28030}
}
EUVIMED